Home › T-Cell Lymphoma › New York › New York City
T-Cell Lymphoma clinical trials in New York City, NY
13 studies for T-Cell Lymphoma are looking for participants at sites in and around New York City (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
RecruitingPhase 1
- Columbia University, New York
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
RecruitingPhase 2
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- Memorial Sloan Kettering Cancer Center, New York
- NYP/Weill Cornell Medical Center, New York
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
RecruitingPhase 3
- Icahn School of Medicine at Mount Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
- Weill Cornell Medicine, New York
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
RecruitingPhase 1/2
- Memorial Sloan Kettering Cancer Center, New York
A Study of Ruxolitinib and Duvelisib in People With Lymphoma
RecruitingPhase 1
- Memorial Sloan Kettering Cancer Center, New York
CD4CAR for CD4+ Leukemia and Lymphoma
RecruitingPhase 1
- Albert Einstein Health Network, New York
A Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas
RecruitingPhase 1/2
- Memorial Sloan Kettering, New York
A Registry for People With T-cell Lymphoma
RecruitingObservational study
- Weill Cornell Medical Center (Data Collection Only), New York
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma
RecruitingPhase 2
- Icahn School of Medicine at Mount Sinai, New York
CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL)
RecruitingPhase 1
- Columbia University Irving Medical Center, New York
Tissue Repository: CTCL Collection Protocol
RecruitingObservational studyHealthy volunteers welcome
- Columbia University Irving Medical Center, New York
MB-105 in Patients With CD5 Positive T-cell Lymphoma
RecruitingPhase 2
- Memorial Sloan Kettering Cancer Center, New York
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
RecruitingPhase 1
- Children's Hospital New York-Presbyterian, New York
- Memorial Sloan Kettering Cancer Center, New York
T-Cell Lymphoma trials in other cities
- Philadelphia, PA10 studies
- Baldwin Park, CA9 studies
- Boston, MA9 studies
- Houston, TX8 studies
- Atlanta, GA8 studies
- Rochester, MN6 studies
- Columbus, OH6 studies
- Chicago, IL6 studies
- Seattle, WA6 studies
- New Haven, CT5 studies
- Miami, FL5 studies
- Scottsdale, AZ4 studies
Other studies in New York City
- Breast Cancer136 studies
- Non-Small Cell Lung Cancer121 studies
- Cancer (all types)109 studies
- Prostate Cancer103 studies
- Metastatic Cancer93 studies
- Colorectal Cancer78 studies
- Ovarian Cancer69 studies
- Lung Cancer60 studies
- Multiple Myeloma60 studies
- Pancreatic Cancer60 studies
- Endometrial Cancer52 studies
- Acute Myeloid Leukemia51 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.